Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. - Wikidata - wikimedia - TriplyDB

Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

http://www.wikidata.org/entity/Q40553670

about

Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells Why are tumour blood vessels abnormal and why is it important to know?Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Mural cell associated VEGF is required for organotypic vessel formation Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation Systems biology of pro-angiogenic therapies targeting the VEGF system Gene therapy from the perspective of systems biology.Cationic lipid-coated PEI/DNA polyplexes with improved efficiency and reduced cytotoxicity for gene delivery into mesenchymal stem cells.Correlative Imaging of the Murine Hind Limb Vasculature and Muscle Tissue by MicroCT and Light Microscopy.Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy.Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia.Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.Effects of VEGF temporal and spatial presentation on angiogenesis.Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164 Molecular mediators of angiogenesis.Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation.Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle.Targeted Genome Engineering to Control VEGF Expression in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells: Potential Implications for the Treatment of Myocardial Infarction.Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Early Skeletal Muscle Tissue Formation Granzyme B releases vascular endothelial growth factor from extracellular matrix and induces vascular permeability.Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling Hyperbaric oxygen therapy improves early posttransplant islet function.Controlled multiple growth factor delivery from bone tissue engineering scaffolds via designed affinity Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism.A titratable two-step transcriptional amplification strategy for targeted gene therapy based on ligand-induced intramolecular folding of a mutant human estrogen receptor Strategies for vascularization of polymer scaffolds Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers.Treatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene.Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones.XIAP gene expression protects β-cells and human islets from apoptotic cell death Multilayered microcapsules for the sustained-release of angiogenic proteins from encapsulated cells.Efficient in vivo vascularization of tissue-engineering scaffolds

P2860

Q24337548-7EB7AC80-FF37-4F8A-BCEA-A5B74C99D426 Q24652018-2B716C78-9A34-457C-9930-37870E0A4986 Q26799856-C5A959BC-F548-40A4-9484-C462E9C74697 Q26829783-9288DF84-54B1-4D15-BEF7-18A8BA5AAE34 Q27000351-6B68C009-14C5-4583-AB1B-40BAC6C11E27 Q27348757-EA2E9FF3-F08F-460F-BB92-B95599D4A738 Q28586929-78212E97-FE09-4BFF-A9E3-9C1BE82EBB63 Q30276870-D0B7C59F-FD0B-4F4D-810F-0E538F97D464 Q30430112-CC5894C1-4321-4D37-9772-95C0986F08C0 Q30430438-79B587AE-5B51-473E-B22A-6347E483A6EE Q30560846-67B7937C-0344-4401-9A89-C4EB9EC9D2E3 Q30837730-5ADDA0E0-79F5-485B-A0ED-4C9C8CD8F95D Q33258465-8D723567-8CC2-4723-9252-D22DFDDF9617 Q33443963-D7B8261F-9FA6-42DA-AB57-D091B6721EBE Q33586324-32ED5445-1DED-4067-BAE1-BC694F34672E Q33586957-CCBDD09A-56A0-4591-B6D2-69BF16570E42 Q33620964-2AB8FE60-461E-42BF-AE2E-85C1C1703023 Q33627325-24048E12-B937-4CD5-8983-92F527188244 Q33639474-8AF0984A-451D-47A8-B479-5E590E017E84 Q33653191-C0A72C3A-C936-44B6-B412-3A72AE06C608 Q33668117-52E0A330-5A72-4A85-A4D2-DF2CAE499BA5 Q33684402-49B31FEF-9045-467A-A083-E3EC3C591776 Q33713095-646B3F92-13AA-4815-AB09-6D68F4DCDFAF Q33722274-C57E61B6-25B2-471D-87F1-8A22294D8ACC Q33731734-75536582-4E80-48C1-A2D3-51945A58AE9D Q33792967-AE68375D-C7DD-4D41-A77C-D65B2F7D8F8A Q33818704-9E827306-4FF1-4BF1-9A0E-435823E0DD63 Q33911723-86C33F3C-E35D-41B6-A0B4-653DDD77A7E8 Q34040039-6DB2FBDA-562A-4E1F-8613-AC8E3A15D409 Q34063540-0B72882D-8883-44E2-8670-947F1172B5C2 Q34115816-F1F38C07-1D0A-4E68-BEBD-14A6A73C16AA Q34134386-76820FA2-C82A-4F67-8803-3C255B7615D2 Q34196960-6378B33A-48E0-486D-ADA7-77197BA5A55B Q34211006-A5651AF4-03BD-4C3B-ABDC-66A411DB117B Q34217612-BD57F90E-EFC6-4ABB-B1CD-983A91AA78A5 Q34238103-3EF1005F-476D-4ABD-9093-009320A83D8B Q34241543-35FE9156-8264-49BE-B753-68A18723600E Q34380509-782F2F41-FF3D-4749-B119-6285863CFFE0 Q34386235-1114220F-4DFA-404C-B6A7-920CA44AA12C Q34441892-0AA7DADC-A146-4F1C-BB8E-F89D8E06A4AC

P2860

Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

http://www.wikidata.org/entity/Q40553670

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Microenvironmental VEGF concen ...... mal and aberrant angiogenesis.

@en

type

label

Microenvironmental VEGF concen ...... mal and aberrant angiogenesis.

@en

prefLabel

Microenvironmental VEGF concen ...... mal and aberrant angiogenesis.

@en

P1433

Q40553670-F004C405-E90A-41B6-AD69-A12C1893A073

P1476

Q40553670-8003DF50-5A85-454D-9444-127FAED64C58

P2093

Q40553670-1AC81CFD-93C0-4BA6-B8D0-A7BE4D2E6333

Q40553670-2194020C-8656-40A4-AD55-B90DBB1531E6

Q40553670-392155BF-5429-46E2-9454-167766B3E017

Q40553670-5B03AAE4-372C-4182-9B92-E44A2FDF025A

Q40553670-8A57E02B-0729-4958-AEAB-26966A106997

Q40553670-90D86AD2-3D1E-4DE4-8737-AE51124CEB65

Q40553670-B202734F-EC78-48E5-B71C-FE3C3D029A4F

Q40553670-D83B6209-53A2-4490-B110-9C9CCFB17F6D

P2860

Q40553670-03032161-94D4-4603-BE3C-2709BC68B508

Q40553670-0BBBDF04-2B71-43BF-A83B-2430669ACA02

Q40553670-137E051C-B5AE-4F63-8143-1461C9B5AFB7

Q40553670-1521873D-8834-4484-A0E0-1E612182FF99

Q40553670-1A8E5563-DB1A-48ED-B8DF-B3AEE185E3B3

Q40553670-1F1C9666-D21E-4617-9C2A-B5F0382DBE4A

Q40553670-20A80FFC-A4B4-465F-BE51-AEEC6F64EAC0

Q40553670-2238D05A-D230-4A00-9F4A-B5E5A03B78E4

Q40553670-249BA9F1-0513-404E-9E95-F64CB6D3E2DF

Q40553670-28F9E8F4-935B-4AED-8E2A-F1F9A6CC58D9

P304

Q40553670-B1D4E698-F830-48C9-9060-CCE4A1B074A9

P31

Q40553670-38AAB34B-F05F-4663-9BCB-DA5D2FEFEEE6

P356

Q40553670-171E476C-661A-4B0E-BFAF-7154781F8344

P407

Q40553670-DCE083E1-78C3-4DAB-BC44-C66CC39FEBE5

P433

Q40553670-F05C876F-ECE7-46CE-8667-870AE11082F7

P478

Q40553670-D2F5F8C3-C03D-4CCF-A469-5EE8ADB9F6CF

P577

Q40553670-B17B5C71-FE74-4B94-BC95-5C4C792B9C2C

P5875

Q40553670-9BDECC2A-9219-40E5-87DD-F2E5408F6505

P698

Q40553670-60B3E7BB-E387-4BC2-8FF3-F7DE0B9D49A5

P932

Q40553670-86DFC6AE-21D4-4AC8-8871-EF09E803B9A8

P356

P1433

Journal of Clinical Investigation

P1476

Microenvironmental VEGF concen ...... mal and aberrant angiogenesis.

@en

P2093

Andrea Banfi

http://www.w3.org/2001/XMLSchema#string

Clare R Ozawa

http://www.w3.org/2001/XMLSchema#string

Donald M McDonald

http://www.w3.org/2001/XMLSchema#string

Gavin Thurston

http://www.w3.org/2001/XMLSchema#string

Helen M Blau

http://www.w3.org/2001/XMLSchema#string

Matthew L Springer

http://www.w3.org/2001/XMLSchema#string

Nicole L Glazer

http://www.w3.org/2001/XMLSchema#string

Peggy E Kraft

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method

Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis

Angiogenesis in cancer and other diseases

Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Vascular-specific growth factors and blood vessel formation

Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization.

An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes.

P304

516-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI18420

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8691146

http://www.w3.org/2001/XMLSchema#string

P698

14966561

http://www.w3.org/2001/XMLSchema#string

P932

338257

http://www.w3.org/2001/XMLSchema#string